Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17572995 | 0.86 | MCHR1 (0.54) | MCHR1PDK2L3MBTL3USP30NPY5R | |
| Lithium Ion SCHEMBL17559453 | 0.85 | GPR119 (0.47) | MCHR1PDK2L3MBTL3USP30ALDH1A1 | |
| SCHEMBL17559448 | 0.84 | MCHR1 (0.53) | MCHR1PDK2L3MBTL3USP30NPY5R | |
| SCHEMBL95193 | 0.84 | MCHR1 (0.53) | MCHR1PDK2L3MBTL3USP30NPY5R | |
| SCHEMBL6538705 | 0.84 | CCR5 (0.57) | MCHR1PDK2L3MBTL3NPY5R | |
| SCHEMBL17559476 | 0.82 | PDK2 (0.52) | MCHR1PDK2L3MBTL3USP30NPY5R | |
| SCHEMBL20772948 | 0.75 | MCHR1 (0.47) | MCHR1PDK2L3MBTL3NPY5R | |
| SCHEMBL562825 | 0.75 | POLB (0.50) | MCHR1PDK2L3MBTL3NPY5RSMO | |
| SCHEMBL25498560 | 0.74 | LMNA (0.65) | MCHR1PDK2USP30ALDH1A1SMO | |
| SCHEMBL20955964 | 0.73 | PDK2 (0.66) | MCHR1PDK2L3MBTL3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| EP-3189041-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | Ctxt Pty Ltd (AU) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | MCHR1 2275/4885PDK2 2493/4885L3MBTL3 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.